Investing.com - Citius Pharma (NASDAQ: CTXR) reported second quarter EPS of $-0.070, $0.03 worse than the analyst estimate of $-0.040. Revenue for the quarter came in at $0.00 versus the consensus estimate of $0.00.
Citius Pharma's stock price closed at $1.410. It is up 11.020% in the last 3 months and up 57.510% in the last 12 months.
Citius Pharma saw positive EPS revisions and negative EPS revisions in the last 90 days. See Citius Pharma's stock price’s past reactions to earnings here.
According to InvestingPro, Citius Pharma's Financial Health score is "fair performance".
Check out Citius Pharma's recent earnings performance, and Citius Pharma's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar